Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Autoantibody screening in Guillain-Barré syndrome

  • Lleixà, Cinta|||0000-0002-9971-0584
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Franco Leyva, Teresa|||0000-0002-0250-0274
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Suárez Calvet, Xavier|||0000-0002-5314-6607
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Homedes, C.
  • Gutiérrez-Gutiérrez, Gerardo
  • Jimeno-Montero, M. C.
  • Berciano, José|||0000-0001-9261-9748
  • Sedano-Tous, M. J.
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Pardo, Julio|||0000-0001-8807-1310
  • Márquez-Infante, C.
  • Rojas-Marcos, I.|||0000-0003-4142-4283
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Martínez Hernández, Eugenia
  • Morís, Germán|||0000-0001-7608-2194
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Background: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain-Barré syndrome. Methods: Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed. Results: None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors. Conclusion: Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies targeting nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic value; (3) further antigen-discovery experiments may elucidate other potential antigens in GBS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Rajabally, Yusuf
  • Scotton, Sangeeta
  • Jacobs, Bart C.|||0000-0002-8985-2458
  • Baars, Adája Elisabeth|||0000-0001-7842-0871
  • Cortese, Andrea
  • Vegezzi, Elisa|||0000-0001-8776-6831
  • Höftberger, Romana|||0000-0002-5769-1100
  • Zimprich, Fritz|||0000-0002-6998-5480
  • Roesler, Cornelia
  • Nobile-Orazio, Eduardo|||0000-0003-2624-8138
  • Liberatore, Giuseppe|||0000-0003-2666-1678
  • Hiew, Fu Liong|||0000-0002-4708-3734
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Carvajal, Alejandra
  • Piñar Morales, Raquel|||0000-0003-3490-4932
  • Usón-Martín, Mercedes
  • Albertí, Olalla
  • López Pérez, María Ángeles
  • Márquez, Fabian
  • Pardo-Fernández, Julio
  • Muñoz-Delgado, Laura|||0000-0002-8818-1824
  • Cabrera-Serrano, Macarena|||0000-0003-3109-6095
  • Ortiz-Castellon, Nicolau|||0000-0001-9544-2642
  • Bartolomé, Manuel
  • Duman, Özgür
  • Bril, Vera
  • Segura-Chávez, Darwin
  • Pitarokoili, Kalliopi
  • Steen, Claudia
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Background and ObjectivesTo study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN).MethodsPatients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up.ResultsForty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients.DiscussionAnti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases.Classification of EvidenceThis study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab.